Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vectus BiosystemsASX:VBS -13.33%15 EV-to-EBIT is -5.88 as of Jul. 29, 2026. GuruFocus rates ASX:VBS with a GF Score™ of 15/100. The stock has 2 warning signs investors should review. Among 381 Biotechnology companies, Vectus Biosystems ranks worse than 262466.93% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Vectus Biosystems's Enterprise Value for the quarter that ended in Dec. 2025 was A$9.73 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vectus Biosystems's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$-1.39 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vectus Biosystems EV-to-EBIT Related Terms
Vectus Biosystems EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Vectus Biosystems's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:VBS vs VRTX, REGN, RVMD: EV-to-EBIT Comparison
For the Biotechnology subindustry, Vectus Biosystems's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vectus Biosystems EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vectus Biosystems's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Vectus Biosystems's EV-to-EBIT falls into.
Vectus Biosystems's current Enterprise Value is A$8.16 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vectus Biosystems's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$-1.39 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vectus Biosystems (ASX:VBS) has a EV-to-EBIT of -5.88 as of Jul. 29, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Vectus Biosystems and its competitors. According to the industry distribution chart, Vectus Biosystems ranks #999999 out of 381 companies in the Biotechnology industry.
Is Vectus Biosystems' EV-to-EBIT too high?
Vectus Biosystems' current EV-to-EBIT is -5.88. Based on the distribution chart, Vectus Biosystems ranks #999999 out of 381 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vectus Biosystems has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Vectus Biosystems' EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vectus Biosystems ranks #999999 out of 381 companies for EV-to-EBIT. This places Vectus Biosystems in the lower half of its industry. The industry median EV-to-EBIT is 12.81. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 12.81, based on 381 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Vectus Biosystems and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 12.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vectus Biosystems's current EV-to-EBIT is -5.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vectus Biosystems stock overvalued right now?
Vectus Biosystems (ASX:VBS) has a current EV-to-EBIT of -5.88. The current EV-to-EBIT is -5.88. Vectus Biosystems' overall GF Score™ is 15/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Vectus Biosystems (ASX:VBS), the current EV-to-EBIT is -5.88 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company has developed and patented various novel compounds for the treatment of chronic fibrosis, including heart, kidney, liver, and lung fibrosis. Its drug candidate VB0004, is aimed at inhibiting and reversing the loss of functional tissue due to fibrosis, is in its human trials phase.
15GF Score
Get the complete analysis for ASX:VBS
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VBS has been successfully added to your 
